Effects of Nitric Oxide Donor Antioxidants Containing the Phenol Vitamin E Substructure and a Furoxan Moiety on Ischemia/Reperfusion Injury

Abstract

Nitric oxide (NO) donor antioxidants are a class of polyvalent drugs which is the focus of great interest today. They are potentially useful for the treatment of many forms of cardiovascular diseases, including the myocardial ischemia/reperfusion (I/R) damage which seems to be due to both a burst of reactive oxygen species (ROS) and a reduced release of NO during reperfusion. In this paper the results of a study on the ability of new NO-donor antioxidants containing the phenol vitamin E substructure and furoxan moiety to attenuate I/R damage are reported. The compounds under study are obtained by combining the phenol moiety (6-hydroxy-2,2,5,7,8-pentamethylchroman) present in vitamin E with differently substituted furoxan substructures endowed with different capacity of NO-release. Their antioxidant and NO-dependent vasodilator activities are reported. The I/R experiments were performed on isolated rat heart preparations perfused at a constant flow. After 20 min of stabilization, global ischemia was obtained by interrupting the perfusion for 30 min. After ischemia the hearts were reperfused for 2 h. The compounds were added to the perfusion buffer during the first 20 min of reperfusion. At the end of each experiment, the infarct size was measured with nitro-blue tetrazolium. From the results it appears that the limitation of the infarct area is favoured by an appropriate balance between NO-donor and antioxidant properties and that these two actions are synergic.

Key words

Antioxidants - Furoxans - Ischemia/reperfusion - Multitarget drugs - Myocardial protection - Nitric oxide donors

• References

• 1 Ambrosio G, Zweier JL, Duilio C, Kuppusamy P, Santoro G, Elia PP et al. Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. J Biol Chem. 1993; 268: 18532-41
• 2 Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production of reactive oxygen species by mitochondria. J Biol Chem. 2003; 278: 36027-31
• 3 Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res. 2004; 61: 461-70
• 4 Margaill I, Plotkine M, Lerouet D. Antioxidant strategies in the treatment of stroke. Free Radical Biol Med. 2005; 39: 429-43
• 5 Ebeerhardt K. Reactive oxygen metabolites: chemistry and medical consequence. Boca Raton: CRC Press; 2001
• 6 Marczin N, El-Habashi N, Hoare GS, Bundy RE, Yacoub M. Antioxidants in myocardial ischemia-reperfusion injury: therapeutic potential and basic mechanisms. Arch Biochem Biophys. 2003; 420: 222-36
• 7 Kutala VK, Khan M, Mandal R, Potaraju V, Colantuono G, Kumbala D et al. Prevention of postischemic myocardial reperfusioin injury by the combined treatment of NCX-4016 and tempol. Cardiovasc Pharmacol. 2006; 48: 79-87
• 8 Hamilton KL. Antioxidants and cardioprotection. Med Sci Sport Exer. 2007; 39: 1544-53 and references therein
• 9 Lefer AM, Hayward R. The role of nitric oxide in ischemia-reperfusion. In: Loscalzo J, Vita JA. eds. Nitric oxide and the cardiovascular system. Totowa: Humana Press; 2000: 357-380
• 10 Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc Res. 2004; 61: 402-13
• 11 Iwase H, Robin E, Guzy RD, Mungai PT, Hoek Vanden TL, Chandel NS et al. Nitric oxide during ischemia attenuates oxidant stress and cell death during ischemia and reperfusion in cardiomyocytes. Free Radical Biol Med. 2007; 43: 590-9
• 12 Willmot M, Gray L, Gibson C, Murphy S, Bath PMW. A systematic review of nitric oxide donors and L-arginine in experimental stroke; effects on infarct size and cerebral blood flow. Nitric Oxide Biol Ch. 2005; 12: 141-9
• 13 Das S, Falchi M, Bertelli A, Maulik N, Das DK. Attenuation of ischemia/reperfusion injury in rats by the anti-inflammatory action of resveratrol. Arzneimittelforschung. 2006; 56: 700-6
• 14 Boschi D, Tron GC, Lazzarato L, Chegaev K, Cena C, Di Stilo A et al. NO-donor phenols: a new class of products endowed with antioxidant and vasodilator properties. J Med Chem. 2006; 49: 2886-97
• 15 Chegaev K, Lazzarato L, Rolando B, Marini E, Tosco P, Cena C et al. NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterisation. J Pineal Res. 2007; 42: 371-85
• 16 Cena C, Chegaev K, Balbo S, Lazzarato L, Rolando B, Giorgis M et al. Novel antioxidant agents deriving from molecular combination of vitamin C and NO-donor moieties. Bioorg Med Chem. 2008; 16: 5199-206
• 17 Bohn H, Brendel J, Martorana PA, Schönafinger K. Cardiovascular actions of the furoxan CAS1609, a novel nitric oxide donor. Br J Pharmacol. 1995; 114: 1605-12
• 18 Mastrocola R, Aragno M, Betetto S, Brignardello E, Catalano MG, Danni O et al. Pro-oxidant effect of dehydroepian-drosterone in rats is mediated by PPAR activation. Life Sci. 2003; 73: 289-99
• 19 Penna C, Alloatti G, Cappello S, Gattullo D, Berta G, Mognetti B et al. Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation. Am J Physiol Heart Circ Physiol. 2005; 288: H2512-20
• 20 Penna C, Mancardi D, Rastaldo R, Losano G, Pagliaro P. Intermittent activation of bradykinin ß2 receptors and mitochondrial KATP channels trigger cardiac postconditioning through redox signaling. Cardiovasc Res. 2007; 75: 168-77
• 21 Feelisch M, Shönafinger K, Noack E. Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans. Biochem Pharmacol. 1992; 44: 1149-57
• 22 Razavi HM, Hamilton JA, Feng Q. Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and hearth failure. Pharmacol Ther. 2005; 106: 147-62